Innate Pharma - Asset Resilience Ratio
Innate Pharma (IPHA) has an Asset Resilience Ratio of 6.80% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Innate Pharma total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Innate Pharma's Asset Resilience Ratio has changed over time. See Innate Pharma shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Innate Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Innate Pharma (IPHA) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.32 Million | 6.8% |
| Total Liquid Assets | $6.32 Million | 6.80% |
Asset Resilience Insights
- Limited Liquidity: Innate Pharma maintains only 6.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innate Pharma Industry Peers by Asset Resilience Ratio
Compare Innate Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Innate Pharma (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Innate Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.94% | $14.37 Million | $111.06 Million | +0.47pp |
| 2023-12-31 | 12.47% | $21.85 Million | $175.19 Million | +4.17pp |
| 2022-12-31 | 8.30% | $17.26 Million | $207.86 Million | +2.29pp |
| 2021-12-31 | 6.01% | $16.08 Million | $267.50 Million | +1.18pp |
| 2020-12-31 | 4.83% | $14.85 Million | $307.42 Million | +0.85pp |
| 2019-12-31 | 3.98% | $15.98 Million | $401.36 Million | +0.61pp |
| 2018-12-31 | 3.37% | $15.22 Million | $451.22 Million | -3.19pp |
| 2017-12-31 | 6.57% | $16.74 Million | $255.02 Million | -1.17pp |
| 2016-12-31 | 7.74% | $21.78 Million | $281.58 Million | -19.41pp |
| 2015-12-31 | 27.14% | $83.04 Million | $305.96 Million | +21.68pp |
| 2014-12-31 | 5.46% | $4.95 Million | $90.69 Million | +0.11pp |
| 2013-12-31 | 5.35% | $2.99 Million | $55.88 Million | +1.14pp |
| 2012-12-31 | 4.21% | $2.03 Million | $48.30 Million | -1.55pp |
| 2010-12-31 | 5.76% | $2.76 Million | $48.01 Million | +1.48pp |
| 2009-12-31 | 4.28% | $2.75 Million | $64.22 Million | -33.43pp |
| 2008-12-31 | 37.70% | $22.95 Million | $60.86 Million | -38.78pp |
| 2007-12-31 | 76.48% | $48.30 Million | $63.15 Million | -1.01pp |
| 2006-12-31 | 77.49% | $53.66 Million | $69.25 Million | +13.87pp |
| 2005-12-31 | 63.62% | $15.76 Million | $24.77 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more